| Literature DB >> 36090105 |
Ainhoa Revilla-Guarinos1, Philipp F Popp1, Franziska Dürr1, Tania Lozano-Cruz2,3,4, Johanna Hartig1, Francisco Javier de la Mata2,3,4, Rafael Gómez2,3,4, Thorsten Mascher1.
Abstract
Over the course of the last decades, the continuous exposure of bacteria to antibiotics-at least in parts due to misprescription, misuse, and misdosing-has led to the widespread development of antimicrobial resistances. This development poses a threat to the available medication in losing their effectiveness in treating bacterial infections. On the drug development side, only minor advances have been made to bring forward novel therapeutics. In addition to increasing the efforts and approaches of tapping the natural sources of new antibiotics, synthetic approaches to developing novel antimicrobials are being pursued. In this study, BDTL049 was rationally designed using knowledge based on the properties of natural antibiotics. BDTL049 is a carbosilane dendritic system with bow-tie type topology, which has antimicrobial activity at concentrations comparable to clinically established natural antibiotics. In this report, we describe its mechanism of action on the Gram-positive model organism Bacillus subtilis. Exposure to BDTL049 resulted in a complex transcriptional response, which pointed toward disturbance of the cell envelope homeostasis accompanied by disruption of other central cellular processes of bacterial metabolism as the primary targets of BDTL049 treatment. By applying a combination of whole-cell biosensors, molecular staining, and voltage sensitive dyes, we demonstrate that the mode of action of BDTL049 comprises membrane depolarization concomitant with pore formation. As a result, this new molecule kills Gram-positive bacteria within minutes. Since BDTL049 attacks bacterial cells at different targets simultaneously, this might decrease the chances for the development of bacterial resistances, thereby making it a promising candidate for a future antimicrobial agent.Entities:
Keywords: Bacillus subtilis; antimicrobial resistance; carbosilane dendritic system; cell envelope stress response; drug design; mode of action; whole-cell biosensors
Year: 2022 PMID: 36090105 PMCID: PMC9459136 DOI: 10.3389/fmicb.2022.912536
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Figure 1Synthesis, structure, and properties of the cationic carbosilane derivative used in this study. Synthetic procedure for the formation of compound BDTL49 (A) and its corresponding chemical structure (B). G1 denotes first generation of the carbosilane scaffold. Molecular weight of 964 Daltons. The compound is air and water stable, soluble in protic solvents like water or methanol, and non-soluble in organic solvents.
Minimal inhibitory concentration (MIC) and minimal bactericidal concentrations (MBC) of depicted antibiotics against B. subtilis W168.
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
| 6.25 | 4 | 4 | 2–4 | 1 | 0.5 | 0.0625 |
|
| 6.25 | 8 | 4–8 | 32 | 0.5 | 0.5 | 0.125–0.25 |
MIC values are shown at 8 h timepoints and MBC was determined after 24 h (see Materials and methods). All concentrations are shown in μg ml−1.
Figure 2RNA-seq results upon BDTL049 treatment. (A) Volcano plot of differential expressed Bacillus subtilis genes. (B) Genes in (A) were clustered according to their Subtiwiki (Zhu and Stulke, 2018) classification. Upregulated genes are marked in light gray whereas downregulated genes are highlighted in black. For applied cut-off values regarding significance see the section “Materials and methods.”
Selection of the RNA-seq profile of differential expressed genes in B. subtilis upon BDTL049 exposure.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| 8.22 | 2.8·10−34 | LiaR | Protection against envelope stress | Cell envelope |
|
| 6.47 | 1.1·10−113 | CodY | Biosynthesis of branched-chain amino acids | Amino acid/ nitrogen metabolism |
|
| 6.31 | 8.4·10−103 | YlxR | Biosynthesis of histidine | Amino acid/ nitrogen metabolism |
|
| 6.23 | 6.2·10−129 | TnrA, CodY, CcpA | Biosynthesis of branched-chain amino acids | Amino acid/ nitrogen metabolism |
|
| 6.13 | 4.9·10−67 | SigW | Control of membrane fluidity | Cell envelope |
|
| 5.98 | 1.6·10−115 | N/A | Putative methionine synthase | Amino acid/ nitrogen metabolism |
|
| 5.26 | 2.9·10−125 | N/A | Biosynthesis of methionine | Amino acid/ nitrogen metabolism |
|
| 5.12 | 1.8·10−53 | CodY | Biosynthesis/acquisition of branched-chain amino acids | Amino acid/ nitrogen metabolism |
|
| 5.08 | 3.0·10−88 | N/A | Sulfur metabolism / cysteine breakdown | Protein of unknown function |
|
| 4.74 | 4.1·10−38 | WalR | Protection against envelope stress | Cell envelope |
|
| −2.85 | 7.2·10−6 | SigG | Unknown | Sporulation |
|
| −2.91 | 1.0·10−24 | WalR | Cell wall synthesis, cell elongation | Cell envelope |
|
| −2.95 | 1.2·10−28 | SigA | Cell wall synthesis | Cell envelope |
|
| −3.06 | 5.5·10−6 | PurR | Hypoxanthine and guanine uptake | Transporter |
|
| −3.06 | 4.5·10−10 | PurR | Purine salvage and interconversion | Nucleotide metabolism |
|
| −3.09 | 2.5·10−17 | N/A | Purine uptake | Transporter |
|
| −3.15 | 6.5·10−7 | PyrR | Regulation of pyrimidine biosynthesis | Nucleotide metabolism |
|
| −3.17 | 9.9·10−18 | N/A | Putative purine-cytosine permease | Transporter |
|
| −3.45 | 5.3·10−25 | WalR, PhoP | May be involved in cell wall metabolism | Cell envelope |
|
| −3.98 | 7.0·10−61 | WalR, Spo0A, SigH, and SigI | Major autolysin, cell elongation, and separation | Cell envelope |
Top 10 up- and downregulated genes are shown. For full dataset, see Supplementary Table 1.
Depicted values are representative of the highest differential expressed gene in cases of operons.
According to Subtiwiki (Zhu and Stulke, 2018).
Figure 3Sensitivity of Bacillus subtilis toward BDTL049, and induction of whole cell biosensors by BDTL049. (A) The effect of the addition of increasing concentrations of BDTL049 on the growth of exponentially growing wild type cells (B. subtilis W168) was determined by monitoring OD600 over time. The compound concentrations are indicated below the graph. (B–E) Induction of the P (B,D) and P (C,E) promoters by BDTL049 in liquid media. The effect of antibiotic exposure on growth is indicated as OD600 (B,C), and promoter induction as relative luminescence units by OD600 (D,E). The time of antibiotic addition is indicated by a vertical dashed line. The antibiotic concentrations used are color-coded according to graph (A). The results presented in (B–E) correspond to strains TMB2299 (P) and TMB3822 (P). All experiments were performed at least in triplicate. Means and SDs are depicted.
Figure 4BDTL049 depolarizes the membrane and leads to pore formation. (A) Plate reader bulk measurement using the voltage-sensitive dye Disc3(5), showing membrane depolarization effects of wild type Bacillus subtilis cells upon treatment with different concentrations of the SynAnt BDTL049. The time point of compound addition is indicated by a dashed line. The peptide antibiotic Gramicidin as well as untreated cells are depicted and serve as controls. (B) Exemplary phase contrast (right panels) and fluorescence microscopy pictures of wild type B. subtilis cells stained with the voltage-sensitive dye Disc3(5) (left panels) and the DNA binding dye Sytox Green (middle panels) in the absence or presence of 4 μg ml−1 BDTL049. Incubation of cells with compounds was set to 5 min or as stated otherwise. As positive controls, cells were treated with 9.5 μg ml−1(equivalent to 5 μM) Gramicidin (depolarization without pore formation) or 16.7 μg ml−1 (equivalent to 5 μM) Nisin (depolarization through pore formation). (C) Scatter plot showing fluorescence intensities of Disc3(5) and Sytox Green derived from individual cells (n > 200). The data shown in graphs (A,C) derive from at least three independent biological replicates.
Bacterial strains used in this study.
| Strain | Description | Source /reference |
|---|---|---|
| F-mcrA Δ( | Lab collection | |
|
| Spanish Type Culture Collection (CECT) | |
|
| Spanish Type Culture Collection (CECT) | |
|
| ||
| W168 | Wild type; | Lab collection |
|
| ||
| TMB1620 | W168 |
|
| TMB2009 | W168 | Lab collection |
| TMB2299 | W168 | Lab collection |
| TMB3417 | W168 | Lab collection |
| TMB3441 | W168 | Lab collection |
| TMB3561 | W168 | Lab collection |
| TMB3762 | W168 | This study; |
| TMB3763 | W168 | This study; |
| TMB3764 | W168 | This study; |
| TMB3791 | W168 | This study; |
| TMB3822 | W168 |
|
| TMB4071 | W168 | This study; |
| TMB5600 | W168 ∆ |
|
cmr, chloramphenicol resistance.
Vector and plasmids used in this study.
| Name | Description (primers used for cloning/antibiotic resistances) | Source or reference |
|---|---|---|
| Vector | ||
| pBs3C | pAH328 derivative; |
|
| Plasmids | ||
| pBs3C-P | TM5078/TM5079; | This study |
| pBs3C-P | TM5080/TM5081; | This study |
| pBs3C-P | TM5082/TM5083; | This study |
| pBs3C-P | TM5076/TM5077; | This study |
| pBs3C-P | TM5086/TM5087; | This study |
cmr, chloramphenicol resistance, and ampr, ampicillin resistance.
Oligonucleotides used in this study.
| Name and purpose | Description (sequence) | Use | |
|---|---|---|---|
| Promoter fusions | |||
| TM5076 | PyorB-XbaI.fw | AAAAtctagaACGGAGGTCTATATTGTGAG | Whole-cell biosensors |
| TM5077 | PyorB-PstI.rv | AAAActgcagGTTTTGAAATTTTTGGTACTAC | |
| TM5078 | PdinB-XbaI.fw | AAAAtctagaGTGTTCCTCATCTATATCATCAATC | |
| TM5079 | PdinB-PstI.rv | AAAActgcagCGTGTGTATAGCTTTCATTATAC | |
| TM5080 | PyvgS-XbaI.fw | AAAAtctagaTGCTGAAGCATTGGAATAAGTG | |
| TM5081 | PyvgS-PstI.rv | AAAActgcagAAATAGTTGACAAACATAGATGAAATAC | |
| TM5082 | PfabHB-XbaI.fw | AAAAtctagaATCGCATCATCAAATACCTTCC | |
| TM5083 | PfabHB-PstI.rv | AAAActgcagATGGTCAGATTATAACACTAGATATTAG | |
| TM5086 | Pbmr-XbaI.fw | AAAAtctagaCGATGACGGTCTGATTGTCTTTC | |
| TM5087 | Pbmr-PstI.rv | AAAActgcagATCAGCCGCCTTCTATTTTTTCCTTG | |
| Check primers for pBs3C | |||
| TM2262 | pAH328checkfwd | GAGCGTAGCGAAAAATCC | sequencing |
| TM2263 | pAH328checkrev | GAAATGATGCTCCAGTAACC | |
| TM2505 | pAH328 sacA front check fwd | CTGATTGGCATGGCGATTGC | integration of up fragment into genome |
| TM2506 | pAH328 sacA front check rev | ACAGCTCCAGATCCTCTACG | |
| TM5955 | pBS3Clux back check rev | GCAGCCTTTTCCAAACATTCCG | Integration of down fragment into genome |
| TM5956 | pBS3Clux back check fwd | GATAGTTGATATCCAGCAGGATC | |
| TM2507 | pAH328 sacA back check fwd | GTCGCTACCATTACCAGTTG | |
| TM2508 | pAH328 sacA back check rev | TCCAAACATTCCGGTGTTATC | |
Sequences are given in the 5′ → 3’direction. Restriction sites are shown in lowercase.